Aslan Pharmaceuticals Decides to File for Voluntary Liquidation; Shares Plunge

MT Newswires Live07-17

ASLAN Pharmaceuticals (ASLN) shares fell nearly 43% in recent trading Wednesday after its board decided that the company could no longer continue its business due to its liabilities and resolved to apply for liquidation under Cayman law procedures.

The board resolution followed the filing of voluntary liquidation Wednesday by Aslan's Singapore unit and the termination of all employees in both the Singapore and US units, effective immediately, according to Aslan.

The company said its Singapore unit appointed Quantuma as liquidator.

Aslan also said it expects its American depositary shares to be suspended from trading on Nasdaq, with trading to be moved to the over-the-counter market. The company said Monday it had received a staff delisting determination from Nasdaq due to failure to meet continued listing requirements.

Price: 0.63, Change: -0.48, Percent Change: -42.88

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment